EC Number   |
Disease |
PubMed ID |
Title of Publication |
Category |
Confidence Level |
|---|
   3.4.17.23 | COVID-19 |
32734518 |
Classification of the present pharmaceutical agents based on the possible effective mechanism on the COVID-19 infection. |
causal interaction
unassigned |
1
0 |
| 3.4.17.23 | COVID-19 |
32736027 |
Femoral Arterial Thrombosis in a Young Adult after Nonsevere COVID-19. |
causal interaction
unassigned |
4
0 |
| 3.4.17.23 | COVID-19 |
32738184 |
Tumor markers as an entry for SARS-CoV-2 infection? |
diagnostic usage
therapeutic application
unassigned |
1
3
0 |
| 3.4.17.23 | COVID-19 |
32741259 |
Identification of potential anti-TMPRSS2 natural products through homology modelling, virtual screening and molecular dynamics simulation studies. |
causal interaction
therapeutic application
unassigned |
1
3
0 |
| 3.4.17.23 | COVID-19 |
32741970 |
SARS-CoV-2 can infect the placenta and is not associated with specific placental histopathology: a series of 19 placentas from COVID-19-positive mothers. |
causal interaction
diagnostic usage
ongoing research
therapeutic application |
3
2
2
1 |
| 3.4.17.23 | COVID-19 |
32742838 |
COVID-19 in Smokeless Tobacco Habitués: Increased Susceptibility and Transmission. |
unassigned |
0 |
| 3.4.17.23 | COVID-19 |
32743577 |
Interferons and viruses induce a novel primate-specific isoform dACE2 and not the SARS-CoV-2 receptor ACE2. |
causal interaction
ongoing research
unassigned |
1
1
0 |
| 3.4.17.23 | COVID-19 |
32743793 |
COVID-19 and diabetes mellitus: how one pandemic worsens the other. |
diagnostic usage
unassigned |
1
0 |
| 3.4.17.23 | COVID-19 |
32748331 |
Physiological Relevance of Angiotensin Converting Enzyme 2 As a Metabolic Linker and Therapeutic Implication of Mesenchymal Stem Cells in COVID-19 and Hypertension. |
therapeutic application
unassigned |
1
0 |
| 3.4.17.23 | COVID-19 |
32748812 |
Evidence-Based Considerations Exploring Relations between SARS-CoV-2 Pandemic and Air Pollution: Involvement of PM2.5-Mediated Up-Regulation of the Viral Receptor ACE-2. |
causal interaction
therapeutic application
unassigned |
1
1
0 |
